Toulmonde Maud, Démolis Pascal, Houédé Nadine
Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, 33076 Bordeaux Cedex, France.
Exp Ther Med. 2010 Nov;1(6):1005-1011. doi: 10.3892/etm.2010.138. Epub 2010 Aug 26.
Prostate carcinoma is the most common cancer in men. Hormone-resistance is the natural history of this metastatic disease and requires the use of docetaxel as the standard chemotherapy. At present, there is no approved second-line treatment. Here, we report a combination of treatment with Adriamycin and ifosfamide in a series of 7 relatively young patients with an average age of 57 years at the time of diagnosis. Chemotherapy was administered over 3 days with the following schedule: 20 mg/m(2) Adriamycin per day and 1-1.5 mg/m(2) ifosfamide per day, in association with Uromitexan. Treatment was repeated every 3 weeks. Three biological responses, one CT scan response, one bone scan response and two CT scan stabilizations, were obtained. Mean survival following this combination was 6.6 months, and over 26 months after first-line chemotherapy. Tolerance was good with the use of granulocyte-colony stimulating factors. Our observations clearly show that the use of this type of salvage therapy for relatively young patients in good physical condition should be further assessed in a clinical trial, particularly when different lines of chemotherapy are required.
前列腺癌是男性中最常见的癌症。激素抵抗是这种转移性疾病的自然病程，需要使用多西他赛作为标准化疗药物。目前，尚无获批的二线治疗方案。在此，我们报告了在一系列7例相对年轻的患者中联合使用阿霉素和异环磷酰胺进行治疗的情况，这些患者诊断时的平均年龄为57岁。化疗在3天内进行，具体方案如下：每天给予阿霉素20mg/m²，每天给予异环磷酰胺1 - 1.5mg/m²，并联合使用美司钠。每3周重复治疗。获得了3例生物学反应、1例CT扫描反应、1例骨扫描反应和2例CT扫描病情稳定。这种联合治疗后的平均生存期为6.6个月，一线化疗后超过26个月。使用粒细胞集落刺激因子时耐受性良好。我们的观察结果清楚地表明，对于身体状况良好的相对年轻患者，这种挽救性治疗的使用应在临床试验中进一步评估，特别是在需要不同化疗方案时。
